Meanwhile, RRM2 inhibition acted in synergy with gemcitabine in lymphoma (Jones et al., 2011) and with a WEE1 inhibitor in H3K36me3-deficient cancers (Pfister et al., 2015). Here, RRM2 is linked to cancer.